18F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients

被引:79
作者
Li, Panli [1 ,2 ,3 ]
Wang, Xiuying [4 ]
Xu, Chongrui [4 ]
Liu, Cheng [5 ]
Zheng, Chaojie [4 ]
Fulham, Michael J. [3 ,6 ,7 ]
Feng, Dagan [3 ,4 ]
Wang, Lisheng [3 ,8 ]
Song, Shaoli [1 ,3 ,5 ]
Huang, Gang [1 ,2 ,3 ]
机构
[1] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Nucl Med, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, SJTU USYD Joint Res Alliance Translat Med, Shanghai, Peoples R China
[4] Univ Sydney, Sch Comp Sci, Biomed & Multimedia Informat Technol Res Grp, Sydney, NSW 2006, Australia
[5] Fudan Univ, Dept Nucl Med, Shanghai Canc Ctr, Shanghai 200032, Peoples R China
[6] Royal Prince Alfred Hosp, Dept Mol Imaging, Camperdown, NSW, Australia
[7] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[8] Shanghai Jiao Tong Univ, Dept Automat, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Radiomics; PET; CT; Breast cancer; NAC; pCR; YOUNG-WOMEN; 3D SLICER; RECOMMENDATIONS; HETEROGENEITY; FEATURES; CRITERIA; UTILITY; RECIST; IMAGES;
D O I
10.1007/s00259-020-04684-3
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is commonly accepted as the gold standard to assess outcome after NAC in breast cancer patients. F-18-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) has unique value in tumor staging, predicting prognosis, and evaluating treatment response. Our aim was to determine if we could identify radiomic predictors from PET/CT in breast cancer patient therapeutic efficacy prior to NAC. Methods This retrospective study included 100 breast cancer patients who received NAC; there were 2210 PET/CT radiomic features extracted. Unsupervised and supervised machine learning models were used to identify the prognostic radiomic predictors through the following: (1) selection of the significant (p < 0.05) imaging features from consensus clustering and the Wilcoxon signed-rank test; (2) selection of the most discriminative features via univariate random forest (Uni-RF) and the Pearson correlation matrix (PCM); and (3) determination of the most predictive features from a traversal feature selection (TFS) based on a multivariate random forest (RF). The prediction model was constructed with RF and then validated with 10-fold cross-validation for 30 times and then independently validated. The performance of the radiomic predictors was measured in terms of area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Results The PET/CT radiomic predictors achieved a prediction accuracy of 0.857 (AUC = 0.844) on the training split set and 0.767 (AUC = 0.722) on the independent validation set. When age was incorporated, the accuracy for the split set increased to 0.857 (AUC = 0.958) and 0.8 (AUC = 0.73) for the independent validation set and both outperformed the clinical prediction model. We also found a close association between the radiomic features, receptor expression, and tumor T stage. Conclusion Radiomic predictors from pre-treatment PET/CT scans when combined with patient age were able to predict pCR after NAC. We suggest that these data will be valuable for patient management.
引用
收藏
页码:1116 / 1126
页数:11
相关论文
共 48 条
[1]   Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach [J].
Aerts, Hugo J. W. L. ;
Velazquez, Emmanuel Rios ;
Leijenaar, Ralph T. H. ;
Parmar, Chintan ;
Grossmann, Patrick ;
Cavalho, Sara ;
Bussink, Johan ;
Monshouwer, Rene ;
Haibe-Kains, Benjamin ;
Rietveld, Derek ;
Hoebers, Frank ;
Rietbergen, Michelle M. ;
Leemans, C. Rene ;
Dekker, Andre ;
Quackenbush, John ;
Gillies, Robert J. ;
Lambin, Philippe .
NATURE COMMUNICATIONS, 2014, 5
[2]   The Impact of Facility Volume on Rates of Pathologic Complete Response to Neoadjuvant Chemotherapy Used in Breast Cancer [J].
Ajmani, Gaurav S. ;
James, Ted A. ;
Kantor, Olga ;
Wang, Chi-Hsiung ;
Yao, Katharine A. .
ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (11) :3157-3166
[3]   PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy [J].
Antunovic, Lidija ;
De Sanctis, Rita ;
Cozzi, Luca ;
Kirienko, Margarita ;
Sagona, Andrea ;
Torrisi, Rosalba ;
Tinterri, Corrado ;
Santoro, Armando ;
Chiti, Arturo ;
Zelic, Renata ;
Sollini, Martina .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (07) :1468-1477
[4]  
Biau G, 2016, TEST-SPAIN, V25, P197, DOI 10.1007/s11749-016-0481-7
[5]   Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer [J].
Caudle, Abigail S. ;
Gonzalez-Angulo, Ana M. ;
Hunt, Kelly K. ;
Liu, Ping ;
Pusztai, Lajos ;
Symmans, W. Fraser ;
Kuerer, Henry M. ;
Mittendorf, Elizabeth A. ;
Hortobagyi, Gabriel N. ;
Meric-Bernstam, Funda .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) :1821-1828
[6]   False Discovery Rates in PET and CT Studies with Texture Features: A Systematic Review [J].
Chalkidou, Anastasia ;
O'Doherty, Michael J. ;
Marsden, Paul K. .
PLOS ONE, 2015, 10 (05)
[7]   Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients [J].
Chen, Rui ;
Ye, Yin ;
Yang, Chengcheng ;
Peng, Yang ;
Zong, Beige ;
Qu, Fanli ;
Tang, Zhenrong ;
Wang, Yihua ;
Su, Xinliang ;
Li, Hongyuan ;
Yang, Guanglun ;
Liu, Shengchun .
BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (01) :35-43
[8]   Cancer Statistics in China, 2015 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Baade, Peter D. ;
Zhang, Siwei ;
Zeng, Hongmei ;
Bray, Freddie ;
Jemal, Ahmedin ;
Yu, Xue Qin ;
He, Jie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132
[9]  
Chinese Anti-Cancer Association CoBCS, 2019, Chinese Journal of Cancer, V29, P609, DOI [l0.19401/j.cnki.10073639.2019.08.009, DOI 10.19401/J.CNKI.1007-3639.2019.08.009]
[10]  
Chu Wei, 2018, Oncotarget, V9, P7088, DOI 10.18632/oncotarget.23195